CCK in anxiety and cognitive processes

Neuroscience and Biobehavioral Reviews

Volumn 22, Issue 6, 1998, Pages 815-825

  Daugé, Valérie ^a   Léna, Isabelle ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

Anxiety and panic; Attention and memory; CCK B 1; CCK B 2; CCK B receptor binding sites; Cholecystokinin; Dopamine; Nucleus accumbens; Stress

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR;

AMNESIA; ANXIETY NEUROSIS; BEHAVIOR; BINDING SITE; COGNITIVE DEFECT; CONFERENCE PAPER; DOPAMINERGIC SYSTEM; HORMONE RECEPTOR INTERACTION; HUMAN; NONHUMAN; PANIC; PRIORITY JOURNAL; STRESS;

ANIMALS; ANXIETY; CHOLECYSTOKININ; COGNITION; HUMANS; PANIC DISORDER; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ;

EID: 0345195970     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(98)00011-6     Document Type: Conference Paper

References (145)

1. Abelson J.L., Nesse R.M. Cholecystokinin-4 and panic. Arch. Gen. Psychiatry. 47:1990;395.
2. Abelson J.L., Nesse R.M., Vinik A. Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder. Biol. Psychiatry. 29:1991;1220-1223.
3. Akiyoshi J., Moriyama T., Isogawa K., Miyamoto M., Sasaki I., Kuga K., Yamamoto H., Yamada K., Fugii I. CCK-4-induced calcium mobilization in T cells is enhanced in panic disorder. J. Neurochem. 66:1996;1610-1615.
4. Anisman H., Kokkinidis L. Effects of scopolamine, D-amphetamine and other drugs affecting catecholamines on spontaneous alternation and locomotor activity in mice. Psychopharmacology. 45:1975;55-63.
5. Baamonde A., Daugé V., Ruiz-Gayo M., Fulga I.G., Turcaud S., Fournié-Zaluski M.C., Roques B.P. Antidepressant-type effects of endogenous enkephalins protected by systemic RB101 are mediated by opioid ∂ and dopamine D1 receptor stimulation. Eur. J. Pharmacol. 216:1992;157-166.
6. Bammert Adams J., Pyke R.E., Costa J., Cutler N.R., Schweizer E., Wilcox C.S., Wisselink P.G., Greiner M., Pierce M.W., Pande A.C. A double-blind, placebo-controlled study of a CCKB receptor antagonist, CI-988, in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 15:1995;428-434.
7. Basso N., Materia A., D'Intinosante V., Ginaldi A., Reilly P., Ruggeri S., Fioravanti M. Effect of ceruletide on pituitary-hypothalamic peptides and on emotion in man. Peptides. 2(Suppl. 2):1981;71-75.
8. Bellier B., McCort-Tranchepain I., Ducos B., Danascimento S., Meudal H., Noble F., Garbay C., Roques B.P. Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells. J. Med. Chem. 40:1997;3947-3956.
9. Birò E., Sarnyai Z., Penke B., Szabò G., Telegdy G. Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats. Neuroendocrinology. 57:1993;340-345.
10. Birò E., Penke B., Telegdy G. Role of different neurotransmitter systems in the cholecystokinin octapeptide-induced anxiogenic response in rats. Neuropeptides. 3:1997;281-285.
11. Bock M.G., Dipardo R.M., Evans B.E., Rittle K.E., Whitter W.L., Veber D.F., Anderson P.S., Friedinger R.M. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J. Med. Chem. 32:1989;13-16.
12. Bradwejn J., Koszycki D., Meterissian G. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can. J. Psychiatry. 35:1990;83-85.
13. Bradwejn J., Koszycki D., Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch. Gen. Psychiatry. 48:1991;603-610.
14. Bradwejn J., Koszycki D., Couëtoux du Tertre A., van Megen H., den Boer J., Westenberg H., Annable L. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch. Gen. Psychiatry. 51:1994;486-493.
15. Bradwejn J., Koszycki D., Paradis M., Reece P., Hinton J., Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol. Psychiatry. 38:1995;742-746.
16. Brambilla F., Bellodi L., Perna G., Garberi A., Panerai A., Sacerdote P. T cell cholecystokinin concentrations in panic disorder. Am. J. Psychiatry. 150:1993;1111-1113.
17. Branchereau P., Böhme G.A., Champagnat J., Morin-Surun M.P., Durieux C., Blanchard J.C., Roques B.P., Denavit-Saubié M. Cholecystokinin-A and cholecystokinin-B receptors in neurons of the brainstem solitary complex of the rat: Pharmacological identification. J. Pharmacol. Exp. Ther. 260:1992;1433-1440.
18. Chang R.S., Lotti V.J. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc. Natl. Acad. Sci. USA. 83:1986;4923-4926.
19. Charrier D., Dangoumau L., Puech A.J., Hamon M., Thiébot M.-H. Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology. 121:1995;127-134.
20. Charpentier B., Durieux C., Pélaprat D., Dor A., Reibaud M., Blanchard J.C., Roques B.P. Enzyme resistant CCK analogs with high affinities for central receptors. Peptides. 9:1988;835-841.
21. Charpentier B., Pélaprat D., Durieux C., Dor A., Reibaud M., Blanchard J.C., Roques B.P. Cyclic cholecystokinin analogues with high selectivity for central receptors. Proc. Natl. Acad. Sci. USA. 85:1988;1968-1972.
22. Chopin P., Briley M. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology. 110:1993;409-414.
23. Costall B., Domemey A.M., Hughes J., Kelly M.E., Naylor R.J., Woodruff G.N. Anxiolytic effects of CCK-B antagonists. Neuropeptides. 19:1991;65-73.
24. Cowley D.S., Bammert Adams J., Pyke R.E., Cook J., Zaccharias P., Wingerson D., Roy-Byrne P.P. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic. Biol. Psychiatry. 40:1996;550-552.
25. Crawley J.N., Fiske S.M., Durieux C., Derrien M., Roques B.P. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism. J. Pharmacol. Exp. Ther. 257:1991;1076-1080.
26. Crawley J.N., Corwin R.L. Biological actions of cholecystokinin. Peptides. 15:1994;731-755.
27. Daugé V., Dor A., Féger J., Roques B.P. The behavioural effects of the CCK8 injected into the medial nucleus accumbens is dependent on the motivational states of the rats. Eur. J. Pharmacol. 163:1989;25-32.
28. Daugé V., Steimes P., Derrien M., Beau N., Roques B.P., Féger J. CCK8 effects on motivational and emotional states of rats involve CCK-A receptors of the postero-median part of the nucleus accumbens. Pharmacol. Biochem. Behav. 34:1989;157-163.
29. Daugé V., Böhme G.A., Crawley J.N., Durieux C., Stutzmann J.M., Féger J., Blanchard J.C., Roques B.P. Investigation of behavioural and electrophysiological responses induced by selective stimulation of CCK-B receptors by using a new highly potent CCK analog, BC264. Synapse. 6:1990;73-80.
30. Daugé V., Derrien M., Blanchard J.C., Roques B.P. The selective CCK-B agonist BC264 injected in the anterolateral part of the nucleus accumbens reduces the spontaneous alternation behaviour of rats. Neuropharmocology. 31:1992;67-75.
31. Daugé, V.; Ladurelle, N.; Derrien, M.; Durieux, C.; Roques, B.P., Potential therapeutic application of CCK antagonists in anxiety and panic disorders. In: Hamon, M.; Ollat, H.; Thiébot, M.-H.; eds. Anxiety: Neurobiology, Clinic and Therapeutic Perspectives. Colloque INSERM, vol. 232. John Libbey EuroText Ltd; 1993:167-176.
32. Daugé, V.; Roques, B.P., Opioid and CCK systems in anxiety and reward. In: Bradwejn, J.; Vasar, E., eds. Cholecystokinin and Anxiety, From Neuron to Behaviour. R.G. Landes Company; 1995:151-171.
33. Dawson G.R., Rupniak N.M.J., Iversen S.D., Curnow R., Tye S., Stanhope K.J., Tricklebank M.D. Lack of effect of CCK-B receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology. 121:1995;109-117.
34. Dellu F., Mayo W., Cherkaoui J., LeMoal M., Simon H. A two trial memory task with automated recording: study in young and aged rats. Brain Res. 588:1992;132-139.
35. Dellu F., Fauchey V., Le Moal M., Simon H. Extension of a new two-trial memory task in the rat: influence of environmental context on recognition processes. Neurobiol. Learn. Memory. 67:1997;112-120.
36. De Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch. Gen. Psychiatry. 46:1989;511-517.
37. Derrien M., Durieux C., Daugé V., Roques B.P. Involvement of D2 dopaminergic receptors in the emotional and motivational responses induced by injection of CCK8 in the posterior part of the rat nucleus accumbens. Brain Res. 617:1993;181-188.
38. Derrien M., Durieux C., Roques B.P. Antidepressant-like effects of CCK-B antagonists in mice: antagonism by naltrindole. Br. J. Pharmacol. 111:1994;956-960.
39. Derrien M., McCort-Tranchepain I., Ducos B., Roques B.P., Durieux C. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol. Biochem. Behav. 49:1994;133-141.
40. de Saint-Hilaire Z., Roques B.P., Nicolaïdis S. Effect of a highly selective central CCK-B receptor agonist: BC264 on rat sleep. Pharmacol. Biochem. Behav. 38:1991;545-548.
41. Deutch A.Y., Cameron D.S. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience. 46:1992;49-56.
42. Dockray, G.J., CCK neurons and receptors in the CNS: introduction. In: Dourish, C.T.; Cooper, S.J.; Iversen, S.D.; Iversen, L.L., eds. Multiple Cholecystokinin Receptors in the CNS. New York: Oxford University Press; 1992:3-7.
43. Dooley D.J., Klamt I. Differential profile of the CCK-B receptor antagonist CI988 and diazepam in the 4-plate test. Psychopharmacology. 112:1993;452-454.
44. Durieux C., Coppey M., Zajac J.M., Roques B.P. Occurence of two cholecystokinin binding sites in guinea-pig brain cortex. Biochem. Biophys. Res. Commun. 137:1986;1167-1173.
45. Durieux C., Pham H., Charpentier B., Roques B.P. Discrimination between CCK receptors of guinea-pig and rat brain by cyclic CCK8 analogues. Biochem. Biophys. Res. Commun. 154:1988;13010-13015.
46. Durieux C., Derrien M., Maldonado R., Valverde O., Blommaert A., Fournié-Zaluski M.C., Roques B.P. CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia: Correlation with in vivo binding affinities and brain penetration. Ann. NY Acad. Sci. 713:1994;355-358.
47. Fekete M., Lengyel A., Hegedüs B., Penke B., Zarandy M., Toth G.K., Telegdy G. Further analysis of the effects of cholecystokinin octapeptide on avoidance behaviour in rats. Eur. J. Pharmacol. 98:1984;79-91.
48. Fink H., Rex A., Marsden C.A. Behavioural and neurochemical effects of CCK-fragments in animal models of anxiety. Behav. Pharmacol. 5(Suppl. 1):1994;30.
49. Flood J.F., Smith G.E., Morley J.E. Modulation of memory processing by cholecystokinin: Dependence on the vagus nerve. Science. 236:1987;832-833.
50. Flood J.F., Garland J.S., Morley J.E. Evidence that cholecystokinin-enhanced retention is mediated by changes in opioid activity in the amygdala. Brain Res. 585:1992;94-104.
51. Floresco S.B., Seamans J.K., Philipps A.G. A selective role for dopamine in the nucleus accumbens of the rat in random foraging but not delayed spatial win-shift-based foraging. Behav. Brain Res. 80:1996;161-168.
52. Fournié-Zaluski M.C., Coric P., Turcaud S., Lucas E., Noble F., Maldonado R., Roques B.P. Mixed-inhibitor-prodrug as a new approach towards systemically active inhibition of enkephalin-degrading-enzymes. J. Med. Chem. 35:1992;2473-2481.
53. Frankland P.W., Josselyn S.A., Bradwejn J., Vaccarino F.J., Yeomans J.S. Activation of amygdala cholecystokinin B receptors potentiates the acoustic startle response in the rat. J. Neurosci. 17:1997;1838-1847.
54. Greenstein R.J., Ybanez M.M., Zhang R.L., Bauman W.A. Is ageing preprogrammed? Observations from the brain/gut axis. Mech. Ageing Dev. 61:1991;113-121.
55. Guimaraés, F.S.; Russo, A.S.; De Aguiar, J.C.; Ballejo, G.; Graeff, F.G., Anxiogenic like effect of CCK8 micro-injected into the dorsal periaqueductal grey of rats in the elevated plus maze. In: Dourish, C.T.; Cooper, S.J.; Iversen, S.V.; Iversen, L.L., eds. Multiple Cholecystokinin Receptors in the CNS. New York: Oxford Science Publications; 1992:149-154.
56. Hadjiivanova C., Kehayov R., Petkov V.V., Amblard M., Martinez J. Behavioural effects of the cyclic cholecystokinin peptide analogue JMV-320. Peptides. 5:1995;815-819.
57. Harper E.A., Roberts S.P., Shankley N.P., Black J.W. Analysis of variation in L-365,260 competition curves in radioligand binding assays. Br. J. Pharmacol. 118:1996;1717-1726.
58. Harro J., Vasar E. Evidence that CCK-B receptors mediate the regulation of exploratory behaviour in the rat. Eur. J. Pharmacol. 193:1991;379-381.
59. Harro J., Oreland L. Cholecystokinin receptors and memory: a radial maze study. Pharmacol. Biochem. Behav. 44:1993;509-517.
60. Harro J., Löfberg C., Rehfeld J.F., Oreland L. Cholecystokinin peptides and receptors in the rat brain during stress. Naunyn-Schmiedeberg's Arch. Pharmacol. 354:1996;59-66.
61. Hendrie C.A., Neill J.C., Shepherd J.K., Dourish C.T. The effects of CCK-A and CCK-B antagonists on activity in the black/white exploration model of anxiety in mice. Physiol. Behav. 54:1993;689-693.
62. Hernando F., Fuentes J.A., Roques B.P., Ruiz-Gayo M. The CCK-B antagonist, L-365,260, elicits antidepressant-type effects in the forced-swimming test in mice. Eur. J. Pharmacol. 261:1994;257-263.
63. Hernando F., Fuentes J.A., Founié-Zaluski M.C., Roques B.P., Ruiz-Gayo M. Antidepressant-like effects of CCK-B receptor antagonists: involvement of the opioid system. Eur. J. Pharmacol. 318:1996;221-229.
64. Hernando F., Fuentes J.A., Ruiz-Gayo M. Impairment of stress adaptative behaviours in rats by the CCK-A receptor antagonist, devazepide. Br. J. Pharmacol. 118:1996;400-406.
65. Hill D.R., Shaw T.W., Woodruff G.N. Species differences in the localization of 'peripheral' type cholecystokinin receptors in the brain. Neurosci. Lett. 79:1987;286-289.
66. Hill D.R., Woodruff G.N. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK329 and L-365,260. Brain Res. 526:1990;276-283.
67. Hökfelt T., Rehfeld J.F., Skirboll L., Ivemark B., Goldstein M., Markey K. Evidence for coexistence of dopamine and CCK in mesolimbic neurones. Nature. 285:1980;476-478.
68. Hökfelt, T.; Holets, V.R.; Staines, W.; Meister, B.; Melander, T.; Schalling, M.; Schutzberg, M.; Freedman, J.; Bjorklund, H.; Olson, L.; Lindh, B.; Elfvin, L.G.; Lundberg, J.M.; Lindgren, J.A.; Samuelsson, B.; Pernow, B.; Terenius, L.; Post, C.; Everitt, B.; Goldstein, M.; Coexistence of neuronal messengers. An overview. In: Hökfelt, T.; Fuxe, K.; Pernow, B., eds. Progress in Brain Research, vol 68. Amsterdam: Elsevier; 1986:33-70.
69. Howbert, J.J.; Lobb, K.L.; Brown, R.F.; Reel, J.K.; Neel, D.A.; Mason, N.R.; Mendelsohn, L.G., A novel series of non-peptide CCK and gastrin antagonists: medicinal chemistry and electrophysiological demonstration of antagonism. In: Dourish, C.T.; Cooper, S.J., eds. Multiple Cholecystokinin Receptors-Progress Toward CNS Therapeutic Targets. London: Oxford University Press; 1992.
70. Huang S.C., Fortune K.P., Wank S.A., Gardner J.D. Multiple affinity states of different cholecystokinin receptors. J. Biol. Chem. 269:1994;26121-26126.
71. Hughes J., Boden P., Costall B. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA. 87:1990;6728-6732.
72. Itoh S., Katsuura G. Cholecystokinin octapeptide prevents extinction of active avoidance behaviour in the rat. Drug Dev. Res. 10:1987;171-175.
73. Itoh S., Katsuura G., Takashima A. Interactions of cholecystokinin, β-endorphin, and their antagonists on passive avoidance behaviour in rats. Can. J. Physiol. Pharmacol. 65:1987;2260-2264.
74. Itoh S., Takashima A., Katsuura G. Preventive effect of cholecystokinin octapeptide on scopolamine-induced memory impairment in the rat. Drug Dev Res. 12:1988;63-70.
75. Itoh S., Takashima A., Igano K., Inouye K. Memory effect of caerulein and its analogs in active and passive avoidance responses in the rat. Peptides. 10:1989;843-848.
76. Itoh S., Takashima A., Maeda Y. Memory impairments induced by peripherally administered cholecystokinin A-type receptor antagonists in rats. Drug Dev. Res. 26:1992;89-99.
77. Izumi T., Inoue T., Tsuchiya K., Hashimoto S., Ohmori T., Koyama T. Effect of the selective CCK-B receptor antagonist LY288513 on conditioned fear stress in rat. Eur. J. Pharmacol. 300:1996;25-31.
78. Jenck F., Martin J.R., Moreau J.-L. Behavioral effects of CCKB receptor ligands in a validated simulation of panic anxiety in rats. Eur. Neuropsychopharmacol. 6:1996;291-298.
79. Johnson N.J.T., Rodgers R.J. Ethological analysis of cholecystokinin (CCK-A and CCK-B) receptor ligands in the elevated plus-maze test of anxiety in mice. Psychopharmacology. 124:1996;335-364.
80. Josselyn S.A., Frankland P.W., Petrisano S., Bush D.E.A., Yeomans J.S., Vaccarino F.J. The CCK-B antagonist, L-365,260, attenuates fear-potentiated startle. Peptides. 16:1995;1313-1315.
81. Jorpes E., Mutt V. Cholecystokinin and pancreozymin, one single hormone? Acta Physiol. Scand. 66:1966;196-202.
82. Katsuura G., Itoh S. Prevention of experimental amnesia by peripherally administered cholecystokinin octapeptide in the rat. Drug Dev. Res. 7:1986;269-276.
83. Katsuura G., Itoh S. Passive avoidance deficit following intracerebroventricular administration of cholecystokinin tetrapeptide amide in rats. Peptides. 7:1986;809-814.
84. Katsuura G., Itoh S. Preventive effect of cholecystokinin octapeptide on experimental amnesia in rats. Peptides. 7:1986;105-110.
85. Katsuura G., Ibii N., Matsushita A. Activation of CCK-A receptors induces elevation of plasma corticosterone in rats. Peptides. 13:1992;203-205.
86. Katz R.J., Schmaltz K. Dopaminergic involvement in attention, a novel animal model. Prog. Neuropsychopharmacol. 4:1981;585-590.
87. Knapp R.J., Vaughn L.K., Fang S.N., Bogert C.L., Yamamura M.S., Hruby V.J., Yamamura H.I. A new highly selective CCK-B receptor radioligand ((3H)N-methyl-Nle28-31)CCK26-33): evidence for CCK-B receptor heterogeneity. J. Pharmacol. Exp. Ther. 255:1990;1278-1286.
88. Kramer M.S., Cutler N.R., Ballenger J.C., Patterson W.M., Mendels J., Chenault A., Shrivastava R., Matzura-Wolfe D., Lines C., Reines S. A placebo-controlled trial of L-365,260, a CCKB antagonists, in panic disorder. Biol. Psychiatry. 37:1995;462-466.
89. Ladurelle N., Keller G., Roques B.P., Daugé V. Effects of CCK8 and of the CCK-B selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens. A microdialysis study in freely moving rats. Brain Res. 628:1993;254-262.
90. Ladurelle N., Roques, Daugé V. The transfer of rats from a familiar to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK8 in the posterior nucleus accumbens. J. Neurosci. 15:1995;3118-3127.
91. Ladurelle N., Keller G., Blommaert A., Roques B.P., Daugé V. The CCK-B agonist, BC264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after intraperitoneal injection in rats. Eur. J. Neurosci. 9:1997;1804-1814.
92. Lee Y.M., Beinborn M., McBride E.W., Lu M., Kolakowski L.F. Jr., Kopin A.S. The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J. Biol. Chem. 268:1993;8164-8169.
93. Lemaire M., Piot O., Roques B.P., Böhme G.A., Blanchard J.C. Evidence for endogenous cholecystokininergic balance in social memory. NeuroReport. 3:1992;925-932.
94. Lemaire M., Böhme G.A., Piot O., Roques B.P., Blanchard J.C. CCK-A and CCKB selective receptor agonists and antagonists modulate olfactory recognition in male rats. Psychopharmacology. 115:1994;435-440.
95. Lemaire M., Barnéoud P., Böhme G.A., Piot O., Haun F., Roques B.P., Blanchard J.C. CCK-A and CCK-B receptors enhance olfactory recognition via distinct neuronal pathway. Learning Memory. 1:1994;153-164.
96. LeMoal M., Simon H. Mesocorticolimbic dopaminergic network: Functional and regulatory roles. Physiol. Rev. 71:1991;155-234.
97. Léna I., Roques B.P., Durieux C. Dual modulation of dopamine release from anterior nucleus accumbens through CCK-B receptor subsites. J. Neurochem. 68:1997;162-168.
98. Léna, I.; Simon, H.; Roques, B.P.; Daugé, V., Opposing effects of two selective CCK-B agonists, on the retrieval phase of a two-trial memory task after systemic injection in the rat. Neuropharmacology (submitted).
99. Lines C., Challenor J., Traub M. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Br. J. Clin. Pharmacol. 39:1995;235-242.
100. Mazurek M.F., Beal F. Cholecystokinin and somatostatin in Alzheimer's disease postmortem cerebral cortex. Neurology. 41:1991;716-719.
101. McCann U.D., Slate S.O., Geraci M., Roscow-Terrill D., Uhde T.W. A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls. Neuropsychopharmacology. 16:1997;229-237.
102. McEwen B.S., Sapolsky R.M. Stress and cognitive function. Curr. Opinion Neurobiol. 5:1995;205-216.
103. McDermott J.R., Dodd P.R., Edwardson J.A., Hardy J.A., Smith A.I. Pathway of inactivation of cholecystokinin octapeptide (CCK8) by synaptosomal fractions. Neurochem. Int. 5:1983;641-647.
104. Mezey E., Reisine T.D., Skirboll L., Beinfeld M., Kiss J.Z. Cholecystokinin in the medial parvocellular subdivision of the paraventricular nucleus: coexistence with corticotropin-releasing hormone. Ann. NY Acad. Sci. 448:1985;152-156.
105. Migaud M., Durieux C., Viereck J., Soroca-Lucas E., Fournié-Zaluski M.C., Roques B.P. The in vivo metabolism of cholecystokinin (CCK8) is essentially ensured by aminopeptidase A. Peptides. 4:1996;601-607.
106. Moran T.H., Robinson P.H., Goldrich M.S., McHugh P.R. Two brain cholecystokinin receptors: implications for behavioural actions. Brain Res. 362:1986;175-179.
107. Morley J.E. Minireview. The ascent of cholecystokinin (CCK) from gut to brain. Life Sci. 30:1982;479-493.
108. Mutt, V., Cholecystokinin: Isolation, structure and function. In: Glass, G.B.J., ed. Gastrointestinal Hormones. New York: Raven Press; 1980:169-203.
109. Nevo I., Becker C., Hamon M., Benoliel J.-J. Stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat: Prevention by diazepam but not ondansetron. J. Neurochem. 66:1996;2041-2049.
110. Palmour R.M., Bradwejn J., Ervin F.R. The anxiogenic effects of CCK-4 in monkeys are reduced by CCK-B antagonists, benzodiazepines or adenosine A2 agonists. Eur. Neuropsychopharmacol. 2:1992;193-195.
111. Palmour, R.M.; Durieux, C.; Roques, B.P.; Bertrand, P.; Capet, M.; Dubroeucq, M.C.; Howbert, J.J.; Woodruff, G.; Bradwejn, J.; Ervin, Fr., Anxiogenic effects of CCK agonists in a non-human primate model: central or peripheral? CCK abstract, Chatham, Cape Cod, USA, 1993.
112. Pavlasevic S., Bednar I., Qureshi G.A., Södersten P. Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. NeuroReport. 5:1993;225-228.
113. 125I) Bolton Hunter CCK8. Functional significance of subregional distribution. Neurochem. Int. 10:1987;495-508.
114. Philipp E., Wilckens T., Friess E., Platte P., Pirke K.-M. Cholecystokinin, gastrin and stress hormone responses in marathon runners. Peptides. 13:1992;125-128.
115. Ploeger G.E., Spruijt B.M., Cools A.R. Spatial localization in the Morris water maze in rats: acquisition is affected by intra-accumbens injections of the dopaminergic antagonist haloperidol. Behav. Neurosci. 108:1994;927-934.
116. Powell K.R., Barrett J.E. Evaluation of the effects of PD 134308 (CI988) a CCK-B antagonist on the punished responding of squirrel monkeys. Neuropeptides. 19:1991;75-78.
117. Pratt J.A., Brett R.R. The benzodiazepine receptor inverse agonist FG7142 induces cholecystokinin gene expression in rat brain. Neurosci. Lett. 184:1995;197-200.
118. Rataud J., Darche F., Piot O., Stutzmann J.M., Böhme G.A., Blanchard J.C. 'Anxiolytic' effect of CCK-antagonists on plus maze behaviour in mice. Brain Res. 548:1991;315-317.
119. Ravard S., Dourish C.T. Cholecystokinin and anxiety. Trends Pharmacol. Sci. 11:1990;271-273.
120. Rehfeld, J.F., CCK and anxiety: introduction. In: Dourish, C.T.; Cooper, S.J.; Iversen, S.D.; Iversen, L.L., eds. Multiple Cholecystokinin Receptors in the CNS. New York: Oxford University Press; 1992:117-120.
121. Rex A., Barth T., Voigt J.-P., Domeney A.M., Fink H. Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety. Neurosci. Lett. 172:1994;139-142.
122. Rose C., Vargas F., Facchinetti P., Bourgeat P., Bambal R.B., Bishop P.B., Chan S.M.T., Moore A.N.J., Ganellin C.R., Schwartz J.C. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature. 380:1996;403-409.
123. Ruiz-Gayo M., Durieux C., Fournié-Zaluski M.C., Roques B.P. Stimulation of ∂-opioid receptors binding of the cholecystokinin CCK-B selective agonist [3H]pBC264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J. Neurochem. 59:1992;1805-1811.
124. Schreiber H., Stolz-Born G., Pietrowsky R., Kornhuber H.H., Fehm H.L., Born J. Improved event-related potential signs of selective attention after the administration of the cholecystokinin analog ceruletide in healthy persons. Biol. Psychiatry. 37:1995;702-712.
125. Sekiguchi R., Moroji J. A comparative study on characterization and distribution of cholecystokinin binding sites among the rat, mouse and guinea-pig. Brain Res. 399:1986;271-281.
126. Seroogy K.B., Schalling M., Brené S., Dargeling A., Chai S.Y., Hökfelt T., Persson H., Brownstein M., Huan R., Dixon J., Filer D., Schlessinger D., Goldstein M. Cholecystokinin and tyrosine hydroxylase messenger RNAs in neurons of rat mesencephalon: Peptide/monoamine coexistence studies using in situ hybridization combined with immunochemistry. Exp. Brain Res. 74:1989;149-162.
127. Shlik J., Vasar E., Bradwejn J. Cholecystokinin and psychiatric disorders. CNS Drugs. 8:1997;134-152.
128. Siegel R.A., Dücker E.M., Fuchs B., Pahnke U., Wuttke W. Responsiveness of mesolimbic, mesocortical, septal and hippocampal cholecystokinin and substance P neuronal system to stress, in the male rat. Neurochem. Int. 6:1984;783-789.
129. Siegel R.A., Dücker E.-M., Pahnke U., Wuttke W. Stress-induced changes in cholecystokinin and substance P concentrations in discrete regions of the rat hypothalamus. Neuroendocrinology. 46:1987;75-81.
130. Singh L., Lewis A.S., Field M.J., Hughes J., Woodruff G.N. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci. USA. 88:1991;1130-1133.
131. Singh L., Field M.J., Hughes J., Menzies R., Oles R.J., Vass C.A., Woodruff G.N. The behavioural properties of C1988, a selective cholecystokinin B receptor antagonist. Br. J. Pharmacol. 104:1991;239-245.
132. Smadja C., Maldonado R., Turcaud S., Fournié-Zaluski M.C., Roques B.P. Opposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacology. 120:1995;400-408.
133. Smadja C., Ruiz F., Coric P., Fournié-Zaluski M.C., Roques B.P., Maldonado R. CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins. Psychopharmacology. 132:1997;227-235.
134. Smith, G.P.; Gibbs, J., Development and proof of CCK hypothesis of satiety. In: Dourish, C.J.; Cooper, S.J.; Iversen, S.D.; Iversen, L.L., eds. Multiple Cholecystokinin Receptors in the CNS. New York: Oxford University Press; 1992:166-182.
135. Taghzouti K., Louilot A., Herman J.P., LeMoal M., Simon H. Alternation behaviour, spacial discrimination and reversal disturbances following 6-OHDA lesions in the nucleus accumbens of the rat. Behav. Neural Biol. 44:1985;354-363.
136. Taghzouti, K.; Léna, I.; Dellu, F.; Roques, B.P.; Daugé, V.; Simon, H., Cognitive enhancing effects in young and old rats of pBC264, a selective CCK-B receptor agonist. Psychopharmacology, in press; 1998.
137. Takashima A., Yokota T., Maeda Y., Itoh S. Pretreatment with caerulein protects against memory impairment induced by protein kinase C inhibitors in the rat. Peptides. 12:1991;699-703.
138. Thinus-Blanc, C.; Exploration and spatial knowledge. In: Thinus-Blanc, C., ed. Animal Spatial Cognition: Behavioral and Neural Approaches. Singapore: World Scientific Publishing; 1997:23-42.
139. van Megen H.J.G.M., Westenberg H.G.M., den Boer J.A., Haigh J.R.M., Traub M. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology. 114:1994;449-455.
140. van Megen H.J.G.M., Westenberg H.G.M., den Boer J.A., Slaap B., van Es-Radhakishun F., Pande A.C. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology. 129:1997;243-248.
141. 3 receptors, antagonizes the anti-exploratory effect of caervlein, an agonist of CCK receptors in the elevated plus-maze. Psychopharmacology. 110:1993;213-218.
142. Voits M., Fink H., Gerhardt P., Huston J.P. Application of 'nose-poke habituation' validation with post-trial diazepam- and cholecystokinin-induced hypo- and hypermnesia. J. Neurosci. Methods. 57:1995;101-105.
143. Wang Z.-J., Rao Z.-R., Shi J.-W. Tyrosine hydroxylase neurotensin or cholecystokinin-containing neurons in the nucleus tractus solitari and projection fibers to the nucleus accumbens in the rat. Brain Res. 578:1992;347-350.
144. Wank S.A., Pisegna J.R., de Weerth A. Cholecystokinin receptor family. Molecular cloning, structure and functional expression in rat, guinea pig and human. Ann. NY Acad. Sci. 713:1994;49-66.
145. Zahm D.S., Brog J.S. On the significance of subterritories in the 'accumbens' part of the ventral striatum. Neuroscience. 50:1992;751-767.